Amyotrophic Lateral Sclerosis
Epigenic Therapeutics and NRG Therapeutics Each Secure ~$60M in Series B Rounds for Epigenetic and Neuroscience Advances
Epigenic Therapeutics; NRG Therapeutics; Series B funding; epigenetic therapy; hepatitis B; hypercholesterolemia; Parkinson’s disease; ALS; biotechnology investment; gene silencing
Amylyx Discontinues Rare Disease Program After Relyvrio Fails to Show Benefit Over Placebo
Amylyx; Relyvrio; AMX0035; progressive supranuclear palsy; ALS; clinical trial failure; rare disease program; placebo; discontinuation
FDA Delays Draw Contrasting Responses: Neurizon Cites Agency Strain, Omeros Takes Softer Tone
FDA delays; Neurizon Therapeutics; Omeros Corporation; regulatory review; NUZ-001; narsoplimab; ALS; transplant drugs; agency staffing shortages; clinical hold
FDA Misses IND Deadline for Coya’s ALS Asset, Citing Resource Constraints
FDA; Coya Therapeutics; IND application; ALS; clinical trial delay; COYA 302; resource shortage
Corcept Highlights Survival Benefit Despite ALS Trial’s Missed Primary Endpoint
Corcept Therapeutics; dazucorilant; ALS; amyotrophic lateral sclerosis; DAZALS trial; survival benefit; phase 2 study; ALSFRS-R; ENCALS 2025
Eli Lilly licenses early-stage ALS drug program from Alchemab in $415M pact
Amyotrophic Lateral Sclerosis, Alchemab, Eli, Eli Lilly
Major Clinical Trial Failures of 2024: Setbacks in Neuroscience and Beyond
Clinical trials, drug development, neuroscience, ALS, Alzheimer’s disease, schizophrenia, Duchenne muscular dystrophy, oncology
Voyager Therapeutics Halts ALS Gene Therapy Development Due to Off-Target Effects
SOD1 ALS gene therapy, Off-target effects, VY9323, siRNA payload, TRACER capsid, Preclinical data, Drug development delay
Dual Hormone Therapies Normalize Sleep Patterns in ALS Mouse Models
Amyotrophic lateral sclerosis (ALS), sleep disturbances, orexin antagonist, melanin-concentrating hormone (MCH), suvorexant, sleep architecture, mouse models
Denali and AbbVie’s ALS Candidates Fail Phase 2/3 Trials, Highlighting Challenges in ALS Research
ALS, Denali Therapeutics, AbbVie, Calico Life Sciences, HEALEY ALS Platform Trial, DNL343, fosigotifator, amyotrophic lateral sclerosis, clinical trials, drug development